Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
High mobility group nucleosomal binding domain 2 pseudogene 6 (HMGN2P6) is a processed pseudogene related by sequence homology to the high mobility group nucleosomal binding domain 2 (HMGN2) gene but does not encode a functional protein. Pseudogenes like HMGN2P6 typically arise by duplication or retrotransposition events, leading to loss of protein-coding capacity due to mutations such as premature stop codons or frameshifts. Although most pseudogenes are nonfunctional, there is increasing evidence that some can regulate their parental genes through various mechanisms at the RNA level, including acting as competitive endogenous RNAs (ceRNAs) or antisense transcripts that modulate gene expression. There is no evidence that HMGN2P6 functions in this regulatory capacity or has any role in disease pathogenesis; it is not recognized as a therapeutic target, receptor, enzyme, transporter, or transcription factor. HMGN2P6 is primarily of genomic and evolutionary interest rather than clinical or pharmacological relevance.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on High mobility group nucleosomal binding domain 2 pseudogene 6 (HMGN2P6).